Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD on May 6, 2020
May 05 2020 - 4:05PM
Business Wire
Company to hold conference call at 8:30 a.m.
ET
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company
focused on leveraging endogenous metabolic modulators (EMMs) to
pioneer a new approach for treating complex diseases and improving
health, today announced that it plans to report top-line data from
AXA1125-003 on May 6, 2020 and will host a conference call at 8:30
a.m. ET that morning. AXA1125-003 is a placebo-controlled,
randomized, multi-arm clinical study assessing the impact of
AXA1125 and AXA1957 on safety, tolerability and effects on
structures and functions of the liver in adult subjects with
nonalcoholic fatty liver disease (NAFLD), as measured by a
comprehensive panel of imaging and soluble biomarkers related to
metabolism, inflammation and fibrosis.
The conference call webcast and accompanying slides will be made
available shortly before the start of the call on the company’s
website at www.axcellahealth.com in the Investors & News
section. To access the call via telephone, please dial
1-866-652-5200 (U.S. toll free) or 1-412-317-6060 (international)
five minutes prior to the start time. For those unable to listen in
live, a webcast archive will be available on the company’s website
for 30 days following the call.
About Axcella’s Clinical Studies
Each of the company’s clinical studies, to date, are or have
been conducted as non-investigational new drug (IND) application
clinical studies under U.S. Food and Drug Administration
regulations and guidance supporting research with food. These
studies evaluate(d) product candidates for safety, tolerability and
effects on the normal structures and functions in humans, including
in individuals with disease. They are not designed or intended to
evaluate a product candidate’s ability to diagnose, cure, mitigate,
treat or prevent a disease. If Axcella decides to further develop a
product candidate as a potential therapeutic, as is the case with
AXA1665 and AXA1125/1957, any subsequent clinical studies will be
conducted under an IND.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation FD. Such disclosures
will be included on the company’s website in the “Investors and
News” section. Accordingly, investors should monitor such portions
of the company’s website, in addition to following its press
releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company focused on
leveraging endogenous metabolic modulators (EMMs) to pioneer a new
approach for treating complex diseases and improving health. The
company’s product candidates are comprised of EMMs and their
derivatives that are engineered in distinct combinations and ratios
to simultaneously impact multiple biological pathways. Axcella’s
pipeline includes lead therapeutic candidates for non-alcoholic
steatohepatitis (NASH) and the reduction in risk of overt hepatic
encephalopathy (OHE) recurrence. Additional muscle- and
blood-related programs are in earlier-stage development. For more
information, please visit www.axcellahealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200505005086/en/
Company/Investor Contact Jason Fredette
jfredette@axcellahealth.com 857.320.2236
Media Contact Azeem Zeekrya HDMZ azeem.zeekrya@hdmz.com
312-506-5244
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2023 to Apr 2024